Colleen Callahan

Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia

David T. Teachey, Simon F. Lacey, Pamela A. Shaw et al. · Cancer Discovery · 2016 · 1.1K citations · Full text

Pharmacy, Immunology, Oncology +17

Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy

Vijay Bhoj, Dimitrios C. Arhontoulis, Gerald Wertheim et al. · Blood · 2016 · 271 citations · Full text

Life Sciences, Cell Biology, Immunology +16

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events

Marcela V. Maus, S. Alexander, Michael R. Bishop et al. · Journal for ImmunoTherapy of Cancer · 2020 · 269 citations · Full text

Life Sciences, Immunology, Oncology +17

Risk-Adapted Preemptive Tocilizumab to Prevent Severe Cytokine Release Syndrome After CTL019 for Pediatric B-Cell Acute Lymphoblastic Leukemia: A Prospective Clinical Trial

Stephan Kadauke, Regina M. Myers, Yimei Li et al. · Journal of Clinical Oncology · 2021 · 212 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Humanized CD19-Targeted Chimeric Antigen Receptor (CAR) T Cells in CAR-Naive and CAR-Exposed Children and Young Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia

Regina M. Myers, Yimei Li, Allison Barz Leahy et al. · Journal of Clinical Oncology · 2021 · 187 citations · Full text

Medicine, Hematology, Oncology +16